Digital Asset DirectHoliday Kick-off!
News Media Group, Inc.
Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/
November 10, 2023 07:00 AM Eastern Standard Time
Video
Digital Asset Direct
News ReleaseHow Over-The-Counter Medicines Could Impact Your Blood Pressure
YourUpdateTV
Would it surprise you to know that nearly half of all adults in the country have elevated blood pressure, and most don’t even know it? Yet only 30% have spoken with a healthcare professional about the adverse effects some over-the-counter medicines can have on their blood pressure. Recently, Dr. Mitch Elkind, American Heart Association’s Chief Clinical Science Officer, conducted a satellite media tour to share precautionary measures that people with high blood pressure need to take before using over-the-counter medications, especially if they have pre-existing conditions or are on other medications. A video accompanying this announcement is available at: https://youtu.be/x7bVSA55fJ0 High blood pressure, (also referred to as hypertension) is when your blood pressure, the force of blood flowing through your blood vessels, is consistently too high. The best way to know if you have high blood pressure it is to have your blood pressure checked. How to use a home blood pressure monitor Be still. Discuss how to use your home blood pressure monitor with your health care professional. Don't smoke, drink caffeinated beverages or exercise within 30 minutes before measuring your blood pressure. Empty your bladder and ensure at least five minutes of quiet rest before measurements. Sit correctly. Sit with your back straight and supported (on a dining chair, rather than a sofa). Your feet should be flat on the floor and your legs should not be crossed. Your arm should be supported on a flat surface, such as a table, with the upper arm at heart level. Make sure the bottom of the cuff is placed directly above the bend of the elbow. Check your monitor's instructions for an illustration or have your health care professional show you how. Measure at the same time every day. It’s important to take the readings at the same time each day, such as morning and evening. It is best to take the readings daily, ideally beginning two weeks after a change in treatment and during the week before your next appointment. Take multiple readings and record the results. Each time you measure, take two readings one minute apart and record the results using a printable (PDF) tracker. If your monitor has built-in memory to store your readings, take it with you to your appointments. Some monitors may also allow you to upload your readings to a secure website after you register your profile. Don't take the measurement over clothes. If you get a high blood pressure reading If your blood pressure is higher than 180/120 mm Hg and you are experiencing signs of possible organ damage such as chest pain, shortness of breath, back pain, numbness/weakness, change in vision or difficulty speaking, do not wait to see whether your pressure comes down on its own. Call 911, as this is an emergency. A single high reading is not an immediate cause for alarm. If you get a reading that is slightly or moderately higher than normal, take your blood pressure a second time and write the results of the two measurements down. Consult your health care professional to verify if there’s a health concern or whether there may be any issues with your monitor. If your blood pressure readings suddenly exceed 180/120 mm Hg, wait five minutes and test again. If your readings are still unusually high, contact your health care professional immediately. You could be experiencing a hypertensive crisis. AHA recommendation The American Heart Association recommends home monitoring for all people with high blood pressure to help the health care professional determine whether treatments are working. Home monitoring, or self-measured blood pressure, is not a substitute for regular visits to your physician. If you have been prescribed medication to lower your blood pressure, don't stop taking your medication without consulting your health care professional, even if your blood pressure readings are in the normal range during home monitoring. Understanding Over-the-Counter (OTC) Medications and High Blood Pressure Look for warnings related to high blood pressure medication. Always read the labels on all over-the-counter medications, especially if you have high blood pressure, also known as hypertension. Look for warnings to those with high blood pressure and to those who take blood pressure medications. If you have high blood pressure and certainly if you are on prescription medication, consult your health care professional before taking any over-the-counter medications or supplements. Be careful with supplements or natural (naturopathic) remedies. There are no special pills, vitamins or drinks that can substitute for prescription medications and lifestyle modifications. Talk to your health care professional before taking any over-the-counter drug or supplement that claims to lower your blood pressure. They may not work as advertised and/or may interfere with other medications. In fact, some can even raise your blood pressure. Decongestants may raise your blood pressure. People with high blood pressure should be aware that the use of decongestants may raise blood pressure or interfere with the effectiveness of some prescribed blood pressure medications. Be aware of over-the-counter cold and flu preparations that contain decongestants as well. Discuss any medications you wish to use with your health care professional. Check the sodium content. Some over-the-counter medications are high in sodium, which can also raise blood pressure. Look at the active and inactive ingredients lists for words like “sodium” or “soda.” Note the amount of sodium in the medication. People with high blood pressure should consume less than 1,500 mg of sodium per day from all sources — one dose of some over-the-counter medications can contain more than a whole day’s allowance. Other drugs and substances that can raise your blood pressure include: Alcohol Amphetamines Antidepressants Atypical antipsychotics (for example, clozapine and olanzapine) Caffeine Cocaine Oral contraceptives Non-steroidal anti-inflammatory drugs, or NSAIDs (for example, ibuprofen and naproxen sodium) Systemic corticosteroids (for example, prednisone and methylprednisolone) Do not stop taking any prescribed medications without discussing with your health care professional. To learn more visit: heart.org/bptools About Talent Mitchell S. V. Elkind, MD, MS, FAAN, FAHA is a tenured Professor of Neurology and Epidemiology at Columbia University, and the Chief Clinical Science Officer at the American Heart Association as of September 2022. He received his medical degree from Harvard Medical School, and he trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston, MA. He completed a fellowship in Vascular Neurology and Neuroepidemiology at Columbia University Medical Center. Dr. Elkind holds a Master’s degree in Epidemiology from Columbia’s Mailman School of Public Health. Dr. Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. He is the second neurologist to serve as President of the American Heart Association (AHA) in its 100 year history, from 2020-2021. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X, or by calling 1-800-AHA-USA1. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
November 09, 2023 10:57 AM Eastern Standard Time
Video
News ReleaseThe Snow Agency Announces TikTok Shop Partnership Ahead of Black Friday/Cyber Monday 2023
Avenue Z
As Black Friday/Cyber Monday 2023 (BFCM) approaches, marketers and eCommerce professionals worldwide are gearing up for one of the biggest shopping events of the year. The Snow Agency, an Avenue Z company, and a leader in digital marketing and eCommerce strategy, is proud to announce its status as an official TikTok Shop Partner. The Snow Agency is now offering brands exclusive access, implementation, and optimization of TikTok's innovative shopping platform for BFCM 2023 and beyond. TikTok Shop, which officially launched in September 2023, is revolutionizing how brands connect with consumers to drive sales. The Snow Agency's novel status solidifies its reputation as a trusted partner to enable and scale brands in the new TikTok Shop ecosystem. TikTok Shop offers an array of selling tools and a vast network of affiliates/influencers, providing a unique opportunity for brands to maximize their revenue and gain dynamic, valuable insights. How Does TikTok Shop Work? TikTok Shop offers brands three dynamic ways to showcase their products to a massive and engaged audience: 1. Live Shopping: Customers can seamlessly shop for products featured by their favorite creators and brands during TikTok LIVE livestreams. TikTok Shop products can be tagged and easily purchased during livestreams. 2. Shoppable Videos: In-feed videos become shopping opportunities as customers can click on product links to make direct purchases via any influencer or brand post. 3. Product Showcase: Brands and creators can set up app-native storefronts, allowing shoppers to purchase products directly within the TikTok app. With over 1 billion active monthly users and an impressive 55% conversion rate for users who make purchases after seeing a brand on TikTok, the platform has become a must-visit destination for e-commerce sellers. Key benefits for sellers include: Higher Conversion Rates: With no redirects to other apps or websites, TikTok Shop offers a seamless shopping experience, resulting in higher conversion rates. Extensive Promotion Tools: Brands can leverage various incentives, discounts, free shipping/subsidiary programs, and participate in exclusive TikTok-sponsored campaigns to promote their businesses. Access to Influencers: TikTok Shop provides access to thousands of creators through its affiliate program, allowing brands to connect and collaborate with niche-specific influencers in a pay-for-performance model. Performance Tracking: Comprehensive dashboards within TikTok Shop enable brands to monitor their performance, track traffic, and gather customer reviews. "As a seasoned marketer and long-time Shopify Plus partner with access to unprecedented e-commerce revenue data from our broad client set, I've witnessed firsthand the incredible revenue-generating potential of TikTok Shop.” said Jon Snow, CEO of The Snow Agency. “With access to thousands of content creators and influencers with both seeding and affiliate options, consumer brands have a tremendous amount of influence power within reach. TikTok Shop is a game-changer for e-commerce sellers.” The Snow Agency, part of the Avenue Z Network, is an award-winning digital social media and influencer agency that offers leading-edge marketing solutions to connect brands and consumers. They build seamless digital experiences that influence consumers to act through targeted Facebook, Instagram, TikTok, YouTube, Google Ads, Email & SMS Marketing, and data-driven content creation. Based in Miami, Florida, the Snow Agency is a proud Shopify Plus, Google, Meta, TikTok, Klaviyo, Attentive and TikTok Shop partner. The Avenue Z Network is a strategic communications & marketing advisory focused on brand performance and business growth. Avenue Z works with mission-driven brands to create an integrated narrative through public relations, search and social branding, influencer marketing and performance media. Avenue Z provides clients with the platform they need to gain exposure and activate messages across all media. The Company is headquartered In Miami, FL with offices in Orlando, New York City and Los Angeles. For more information visit www.AvenueZ.com Contact Details Avenue Z press@avenuez.com Company Website https://avenuez.com/
November 09, 2023 10:24 AM Eastern Standard Time
News ReleaseHow DLP Capital Is Helping Address Housing Crisis Through Strategic Investments
Benzinga
By Austin DeNoce, Benzinga For most, the words “housing crisis” invoke feelings of uncertainty and concern, but it is a very real and long-standing challenge in the U.S. The Government Accountability Office reports that high interest rates and low inventory are contributing to this issue, and it can be particularly challenging for low-income Americans to find affordable housing. Yet, where there is a problem, innovative solutions arise. Enter DLP Capital, a potential game-changer in the housing market. The company is working on the dual objectives of providing affordable housing while offering potentially attractive opportunities for both communities and investors. DLP Capital's Dual Focus: Housing Affordability And Investment DLP Capital, established in 2006, has a history of active involvement in the real estate sector. With founder and CEO Don Wenner leading the company, DLP Capital has executed over 30,000 real estate transactions, translating to a total value of more than $10 billion. The company reports it has more than 25,000 homes and apartment units in its portfolio and $5 billion in assets under management and that it has positively impacted the lives of over 838,000 individuals. Empowering Communities Through Housing Solutions DLP Capital's initiatives aim to address societal challenges. One of their goals is to impact the lives of millions positively while striving to become the largest investor in rental housing. The company also operates according to specific core values including servant leadership, humble confidence, innovation and stewardship, and it believes in transforming lives through community building with safe, attainable housing as a primary mission. The DLP Housing Fund is an open-ended, private real estate fund focusing on making an impact on America’s affordable housing crisis. The goal of this fund is to offer tenants <30% rent-to-income ratios, and the strategy is to preserve attainable rental housing through investments in existing value-add communities. The primary focus is on secondary and tertiary markets in the Sun Belt. For investors, this fund offers monthly preferred returns with 10 to 12% targeted annual net returns and tax sheltering benefits. Other Investment Opportunities And Their Focus The DLP Building Communities Fund is another initiative by DLP Capital that seeks to address the workforce housing crisis in America. The fund’s objectives involve investing in the development and construction of new rental communities, thereby providing attainable housing for those making incomes near the AMI. From an investment standpoint, the fund focuses on debt and equity in Sun Belt markets with strong demand, aiming to provide limited volatility and targeted annual net returns between 11% and 13%. Meanwhile, the DLP Lending Fund serves professional real estate operators by furnishing the capital required for the development of affordable workforce housing. The fund’s data suggests offers of monthly distributions, liquidity and targeted annual net returns ranging from 9% to 10%. DLP Capital's Initiatives – Brief Case Studies DLP Capital's commitment to both community development and investor value becomes evident through specific case studies. DLP Wexford Village DLP Capital acquired the DLP Wexford Village in 2020 for $43 million. Comprising 340 units in 14 buildings, this vast residential complex offers housing ranging from one-bedroom to three-bedroom apartments. Under DLP’s ownership, the Wexford Village community experienced an evolution in resident engagement and support. The company says the staff's proactive approach during the COVID-19 pandemic was particularly noteworthy – they utilized daily video communications to stay connected with residents, expressing gratitude to healthcare workers with treats and helping residents navigate financial assistance programs to maintain housing security. The Boyd Theatre Project Situated in Bethlehem, Pennsylvania, the Boyd Theatre stands as a testament to the rich cultural heritage of the Lehigh Valley. Recognizing its potential and its historical significance, DLP Capital, in collaboration with local developer Rocco Ayvazov, embarked on an ambitious project to rejuvenate this landmark. Their plans involve converting the former movie theater into a multifaceted six-story apartment building. This redevelopment aims to encompass commercial retail space, an underground parking facility and recreational areas such as a pool, fitness center and an exclusive outdoor theater for residents. Overseen by the architectural firm SITIO, the project's completion is anticipated by Q3 of 2024, potentially adding a significant boost to local development. Both case studies underscore DLP Capital's ability to synergize investment objectives with a tangible positive impact on communities, reflecting their overarching strategy in the housing landscape. Balancing Community Impact With Investment Goals As urban landscapes continue to evolve and economic dynamics shift, the challenges surrounding affordable housing will likely persist. Ultimately, housing is about more than structures; it's about building communities, fostering connections and ensuring that individuals have a secure place to call home. And in this intricate dance of community building and real estate development, DLP Capital is a proactive participant. As the housing challenges of our time continue to unfold, entities like DLP Capital could play a crucial role in bridging the gap between housing needs and investment aspirations, seeking to craft a future where both coexist in harmony. For more on DLP and how investors could get involved, click here. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com
November 09, 2023 09:00 AM Eastern Standard Time
Digital Asset DirectQYOU Media's India Influencer Marketing Business Chtrbox Records Largest Revenue Month in History
QYOU Media
Contact Details Doug Barker +1 437-992-4814 shareholder@qyoutv.com Company Website https://www.valuethemarkets.com
November 09, 2023 07:00 AM Eastern Standard Time
Video
News ReleaseCURE ALZHEIMER’S FUND RECEIVES $100,000 DONATION FROM ART BLOCKS AUCTION OF NFTS
Alzheimer’s Disease Research Foundation
Cure Alzheimer’s Fund (CureAlz), a nonprofit dedicated to funding the most promising research to end Alzheimer’s disease, received a $100,000 donation from the sale of generative art created by five celebrated digital artists, organized by Art Blocks in collaboration with The Giving Block. In October, generative art platform Art Blocks hosted reGEN — an exclusive sale of works by five leading artists from around the world, supported by Right Click Save. reGEN unites artists and collectors in the fight against Alzheimer’s disease, with proceeds from the auction donated to Cure Alzheimer’s Fund. reGEN is curated by Alex Estorick and Foteini Valeonti, who have also raised more than $500,000 this year in support of Cure Parkinson’s and The ALS Association. A collaboration with The Giving Block, reGEN supports the global movement of generative artists in fighting neurodegenerative diseases that affects millions globally. The five artists who participated in the auction are Melissa Wiederrecht, Sputniko!, Nat Sarkissian, Robert Hodgin, and Marcelo Soria-Rodriguez. “We are so grateful for the generosity of the five artists, The Giving Block and Art Blocks,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “The creativity embodied by the art and the donations from this event will generate enormous returns in scientific progress. Alzheimer’s robs people of their stories, and it is fitting that a wonderful consequence of the works of self-expression by the five exceptional artists will be scientific research to preserve the stories and selves of others.” Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100% of funds raised going to support research, Cure Alzheimer’s Fund has provided grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, please visit https://www.CureAlz.org/. Contact Details Barbara Chambers +1 978-417-9890 BChambers@CureAlz.org
November 09, 2023 06:45 AM Eastern Standard Time
News ReleaseCigar Association Urges OMB to Reject FDA's Proposed Flavored Cigar Ban
Cigar Association of America
The Cigar Association of America (CAA) said that it asked the Office of Management and Budget (OMB) during a November 6 meeting to withdraw the Food and Drug Administration (FDA) Flavored Cigar Product Standard (FCPS) banning flavors in cigars, which it said would cost the industry nearly $4 billion in sales—up to 47 percent of industry sales—and destroy 16,000 jobs. CAA president David Ozgo stated, “We presented evidence to OMB that FDA’s proposed flavored cigar ban dramatically fails to meet the criteria necessary for such a ban under the Tobacco Control Act, offering little or no public health benefit while having a devastating economic impact on the industry.” Ozgo noted, “FDA claims the product standard will reduce youth usage of cigars and that prohibiting flavored cigars will address health disparities in minority adult subpopulations. CAA showed OMB government data demonstrating that neither of these claims is true.” FDA Ignores Science on Health Effects & Clear Economic Impact In order for FDA to impose a flavored cigar ban through a FCPS, the law requires that the Agency consider: whether the potential product standard is appropriate for the public health, taking into consideration scientific evidence concerning the risks and benefits to the population as a whole; the increased or decreased likelihood that existing users of tobacco products will stop using such products; and, the increased or decreased likelihood that those who do not use tobacco products will start using such products. “FDA’s Flavored Cigar Product Standard fails on all three accounts,” Ozgo charged, “Youth usage rates of cigars, and of flavored cigars in particular, are at all-time lows and these low rates reflect a stable and sustained trend.” The 2022 National Youth Tobacco Survey (“NYTS”) showed past 30‐day youth cigar use at 1.85% and past 30‐day youth flavored cigar use at 0.83%. The recently released 2023 NYTS data showed past 30‐day youth cigar use has declined to 1.6%. While the flavored cigar use data has not yet been released, it is expected to follow the trend at under 1% of use. Other government surveys reflect similar trends. In fact, the most recent Population Assessment of Tobacco and Health Survey (PATH) showed that past 30-day youth usage of cigars was only 0.70% and past 30-day youth usage of flavored cigars was just 0.14%. In addition to unsupported youth usage claims, CAA demonstrated FDA failed to show that adult subpopulation health disparities are associated with flavored cigar use or that banning flavored cigars would remedy these disparities among Black, Non-Hispanic Americans. CAA did so despite the fact that FDA is required by law to base its decisions not on subpopulation impacts but on impacts to the population as a whole. 1 (See note 1) “FDA’s claims aside, there is simply not a pattern of use of these products that raises a concern of public health that can justify eliminating an entire category of products, while depriving adult consumers of the right to choose these products” he said. While the public health case is non-existent, FDA’s proposal would have dramatically negative economic consequences. A recent study by the Policy Navigation Group showed the flavored cigar ban would reduce retail sales by nearly $4 billion, up to 47 percent of industry sales, causing some 16,000 people to lose their jobs. FDA Recently Lost in Court After Ignoring Scientific Evidence CAA and other industry groups recently convinced a court to reject the Agency’s effort to regulate “premium” cigars. More particularly, the judge in the case ruled against the FDA, citing the Agency for ignoring the scientific evidence. The proposed FCPS similarly ignores scientific evidence. Ozgo stated, “Just as it did in 2016 and 2019, we urge OMB to again reject FDA’s flavored cigar proposal. There is little or no public health benefit from the proposed FCPS, but huge negative economic consequences will result. This is as bad as public policy gets. Ultimately, FDA’s proposal is a solution in search of a problem.” CAA is a national trade association representing manufacturers, distributors, importers, suppliers, and all channels of retailers in the cigar industry, and traces its roots back to the 1890s. 1 The most recent PATH data (Wave 6), collected in 2021, reports that, in the overall adult population, Black, Non‐Hispanic use of flavored cigars had fallen to 1.86% from 3.22% in Wave 5 (collected in 2019). Further, in the young adult population (18–25‐year‐olds) the past 30‐day prevalence rate had fallen to 0.76% in Wave 6 from 1.57% in Wave 5. Contact Details Frank Coleman +1 202-223-8204 fcoleman@cigarassociation.com
November 08, 2023 12:30 PM Eastern Standard Time
News ReleaseOPPO and Hasselblad Announced to Co-Develop the Next Generation of HyperTone Camera Systems Following Aesthetics
OPPO
PARIS, FRANCE – Media OutReach - 8 November 2023 – At Paris Photo 2023, one of the world’s largest international art fairs dedicated to photography, Global technology brand OPPO and the legendary camera manufacturer, Hasselblad, today announced a joint venture to co-develop the next generation of HyperTone Camera Systems in 2024. Following aesthetics, HyperTone Camera Systems will usher in a new era in computational photography. The systems will initially arrive in future Find series flagships, providing users with an unprecedented mobile imaging experience beyond imagination. OPPO Imaging Director Oliver Zhang said: “Thanks to the HyperTone Camera System which follows aesthetics, the Find X6 Series is positively received by both the public and professionals. With Find N3 Series, we also brought flagship-level imaging experience for foldables for the first time. I am delighted that our collaboration with Hasselblad has now entered a new phase. By combining classic imaging aesthetics with mobile technology, OPPO and Hasselblad have developed an aesthetic system that is tailored for mobile imaging. In 2024, the two companies will launch the next generation HyperTone Camera Systems and Hasselblad camera experience that promise to continue to set new industry standards.” Bronius Rudnickas, Hasselblad Global Marketing Manager, said: "We are very pleased to see OPPO’s latest advancements in mobile imaging, which allow people to use their smartphone to bring their creativity to life through photography. Our continued collaboration to build the next-generation HyperTone Camera Systems is a huge project, that is not just a simple inheritance of style. Instead, it is a more organic and in-depth integration of the aesthetics and technology between both brands that will provide photography enthusiasts with enhanced image quality and stylized experiences, beyond what’s achievable on typical mobile phones. I am looking forward to sharing the results of our collaboration with all the creators next year." Following aesthetics, OPPO is leading a revolution in mobile imaging As a pioneer in mobile imaging, OPPO is leading a revolution by following aesthetics rather than relying on industry traditions of certain technical specifications. This new approach allows the objective technical process to serve the subjective aesthetic of users. The Photography Aesthetics Feature Quantification Lab is made up of 10% photography technicians, 50% professional photographers, and 40% color experts. Through feature breakdown, solutions planning, and precise tuning, OPPO has created a new photography technology development system, ushering in a new era in computational photography. HyperTone Camera System OPPO’s HyperTone Camera System consists of HyperTone All Main Camera System, HyperTone Image Engine, and HyperTone ProXDR Display, to deliver end-to-end system-level imaging capabilities. In addition to Find series flagships, the technical architecture of HyperTone Camera System will empower multiple OPPO product series in the future, for flagship imaging experience with consistent aesthetics and exceptional quality. To meet users’ mobile imaging needs, HyperTone Camera System offers the first-ever All Main Camera System in the industry. It enables high image qualities for every focal length whether it’s day or night. In the Find N3, OPPO brings the stack pixel technology sensor to foldable phones for the first time, achieving performance similar to a one-inch sensor that can be fitted into a foldable. Following aesthetics, HyperTone Image Engine solves many issues in traditional computational photography, achieving fewer digital artifacts with more computation. Extra HD Algorithm, for example, improves clarity by 30% while reducing noise by 60% by using AI RAW fusion. The new algorithm requires 400% more computing power, but it results in cleaner and clearer details after processing. Photo viewing is an indispensable part of a great imaging experience. HyperTone Camera System comes with the industry-leading HyperTone ProXDR Display. By precisely recording the brightness of 12 million pixels, ProXDR technology can unlock up to eight times more dynamic range on-screen, restoring the natural tone to make viewing photos much more realistic. Additionally, OPPO is also working to make ProXDR compatible with the Ultra HDR standard. Hasselblad Portrait Mode Portrait is not only one of the most popular camera features, but it also represents the most cutting-edge innovation of computational photography. Following aesthetics, Hasselblad Portrait Mode provides portrait photography effects that lead the industry. Through the HyperTone Engine, Hasselblad Portrait Mode initiates delicate tonal changes to create a three-dimensional portrait that avoids brightening the face too much and smoothing out light and shadow. By optimizing with 45 times more skin tone colors, Hasselblad Portrait Mode offers more accurate skin tones. And with Bokeh Flare Portrait, users can get a cinematic bokeh effect that truly simulates the optical out-of-focus effect. Work shot using OPPO phones at Paris Photo In 2023, OPPO launched the imagine IF Project to break through the existing limitations of mobile imaging with global users. As a key part of the project, the OPPO imagine IF Photography Awards 2023 has received over 700,000 submissions from 51 countries and regions. The 26th Paris Photo event will be held in Paris, France between November 9-14, 2023. As the only smartphone brand participating in Paris Photo this year, OPPO presented a series of exceptional images, including the works of world-class photographers and the winning works from the OPPO imagine IF Photography Awards 2023. OPPO's presence at Paris Photo serves as a bridge for fostering cross-cultural communication, revealing new possibilities of mobile imaging to photographers, collectors and artists worldwide. Norwegian photography artist and Hasselblad Master, Tina Signesdottir Hult, acclaimed photography artist and Hasselblad master, Wang Jianjun, renowned fashion photographer and Hasselblad Ambassador, Yin Chao, OPPO imagine IF Photography Awards 2023 winner, Ahei Huan, as well as many other photographers, will attend the festival to witness the first presentation of their work shot using OPPO phones at Paris Photo. About OPPO OPPO launched the "Smiley Face Phone" in 2008, continuing to show technological goodwill and moving forward with a smile. Today, OPPO is innovating the personal technology experience with its Find N folding flagship, Find X imaging flagship and other mobile phones, multiple smart devices such as OPPO Watch and OPPO Pad, and the ColorOS software system. OPPO adheres to technological innovation and operates in more than 60 countries and regions around the world. More than 30,000 OPPO employees are committed to creating a better and smarter life for people. Contact Details Media Contact press@oppo.com Company Website https://oppo.com/en/proposal/
November 08, 2023 11:59 AM Eastern Standard Time
Image
News ReleaseMainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection
Benzinga
By Faith Ashmore, Benzinga Throughout the world, colorectal cancer has emerged as the third most prevalent form of cancer. Traditionally observed in individuals aged 45 and above, this malignancy is now displaying a troubling trend of affecting younger individuals. Startling data indicates a consistent increase in newly diagnosed cases of colorectal cancer among those under the age of 50 over the past few decades. In fact, the National Cancer Institute reports that colorectal cancer has become the leading cause of cancer-related deaths for Americans aged 20 to 59 years old. Despite these alarming statistics, routine colorectal cancer screenings for younger adults remain relatively uncommon due to its perceived rarity within this age group. Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The company reports that the test is the first DNA-based screening test for colorectal cancer in Europe. Mainz recently announced significant advancements with the presentation of its highly anticipated ColoFuture Study results. Originally slated for presentation at the 4th International Conference on Gastroenterology in Paris, the event has been rescheduled from October to December, and Mainz Biomed, in collaboration with the Conference leadership, decided to align the release of the ColoFuture results with the original conference timeline. The ColoFuture study, a comprehensive multinational clinical trial, evaluated the potential integration of innovative gene expression biomarkers (mRNA) into the company's cutting-edge screening test for colorectal cancer (CRC) called ColoAlert. The company reports that this test, which is currently being introduced to markets across Europe and select international regions, has proven to be highly effective and user-friendly. The groundbreaking study results that were presented showcased the following findings: a 94% sensitivity for colorectal cancer (CRC), 97% specificity, and an 80% sensitivity for advanced adenoma (AA). These outcomes reinforce Mainz Biomed's commitment to delivering innovative advancements in cancer detection, and the company reports that they beat competitors whose AA hovers around the 40% number. As the company looks towards the future, it seems to be dedicated to enhancing its portfolio of diagnostic solutions and expanding its presence in global markets. Mainz Biomed also recently announced Tarrin Khairi-Taraki as the Vice President of Commercial Operations, EMEA. Tarrin’s appointment marks an important milestone in Mainz Biomed’s journey towards continued success. As Vice President, Tarrin will be tasked with the commercialization of the company's flagship product, ColoAlert. In his new role, Tarrin will bring his vast expertise and experience to Mainz Biomed's global teams, with a particular focus on driving sales growth and expanding the company's footprint throughout the EMEA region. With his successful track record in sales management and commercial operations at leading life sciences organizations like Alutia (NASDAW: ELUT), Tarrin is poised to advance the company's strategic goals by identifying and executing new market opportunities. His leadership will be instrumental in accelerating Mainz Biomed's growth trajectory and enhancing its impact on the global cancer detection market. “I am thrilled to welcome Tarrin to the Mainz Biomed team,” commented Darin Leigh, Chief Commercial Officer at Mainz Biomed. “With his highly-impressive track record and wealth of experience in the medical diagnostic field, I am confident he’ll play a crucial role in propelling our continued success in the commercialization of ColoAlert®.” With the appointment of Tarrin and the release of data showing efficacy, Mainz Biomed seems poised to disrupt the market and establish itself as a trusted and innovative provider of molecular genetic diagnostic solutions. The company’s commitment to pushing the boundaries of diagnostic technology and growth trajectory seems to be making it a force to be reckoned with in the industry, setting it apart from its competitors. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com
November 08, 2023 09:00 AM Eastern Standard Time
